Scarica l'app Stockscreener
16.12
3.47%
-0.58
Dopo l'orario di chiusura:
16.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$16.70
Aprire:
$16.58
Volume 24 ore:
1.88M
Relative Volume:
1.43
Capitalizzazione di mercato:
$2.81B
Reddito:
-
Utile/perdita netta:
$-382.71M
Rapporto P/E:
-6.1527
EPS:
-2.62
Flusso di cassa netto:
$-325.64M
1 W Prestazione:
+8.77%
1M Prestazione:
+0.19%
6M Prestazione:
-12.82%
1 anno Prestazione:
-47.47%
Intervallo 1D:
$16.07
$16.74
Intervallo di 1 settimana:
$14.47
$17.06
Portata 52W:
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-580-3099
Indirizzo
320 WEST 37TH STREET, NEW YORK, NY
Confronta IMVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
16.12 | 2.63B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-03-03 | Iniziato | Jefferies | Hold |
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
Why Immunovant Stock Blasted Higher Today - Yahoo Finance
Immunovant Reports 'Encouraging' Data on Graves' Disease Treatment; Shares Rise - MarketScreener
What to expect from Immunovant Inc. in the next 30 daysQuarterly Performance Summary & Fast Entry and Exit Trade Plans - Newser
Immunovant Data for Batoclimab Shows Potential for Treating Uncontrolled Graves' Disease - MarketScreener
Immunovant Announces Promising Graves’ Disease Study Results - TipRanks
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients - The Manila Times
Immunovant reports promising remission data for Graves’ disease therapy - Investing.com
Immunovant Reports Promising Six-Month Off-Treatment Data for Batoclimab in Uncontrolled Graves' Disease Patients - Quiver Quantitative
Immunovant Announces Promising Six-Month Follow-Up Data for Batoclimab in Uncontrolled Graves’ Disease Patients, Potentially Disease-Modifying Therapy - Quiver Quantitative
80% of Patients Maintain Normal Thyroid Function: Immunovant's Breakthrough in Graves' Disease Treatment Study - Stock Titan
Using data tools to time your Immunovant Inc. exit2025 Big Picture & Low Risk Entry Point Tips - Newser
Is Immunovant Inc. trending in predictive chart modelsJuly 2025 Summary & Low Risk High Reward Ideas - Newser
Visual analytics tools that track Immunovant Inc. performanceJuly 2025 Sentiment & Community Verified Trade Alerts - Newser
Intraday pattern recognizer results for Immunovant Inc.Market Activity Summary & Real-Time Stock Price Movement Reports - Newser
Using RSI to spot recovery in Immunovant Inc.M&A Rumor & Consistent Growth Stock Picks - Newser
Volume spikes in Immunovant Inc. stock – what they meanRisk Management & Advanced Technical Signal Analysis - Newser
How to use a screener to detect Immunovant Inc. breakoutsJuly 2025 Rallies & Stepwise Trade Signal Implementation - Newser
Applying Elliott Wave Theory to Immunovant Inc.July 2025 Update & Verified Momentum Watchlists - Newser
Immunovant Inc. stock volume spike explainedWeekly Gains Summary & Growth Oriented Trading Recommendations - Newser
Is now a turning point for Immunovant Inc.2025 Risk Factors & Free Fast Entry Momentum Trade Alerts - Newser
Earnings visualization tools for Immunovant Inc.2025 AllTime Highs & Consistent Return Strategy Ideas - Newser
Is Immunovant Inc. stock entering bullish territoryQuarterly Earnings Report & Fast Exit/Entry Strategy Plans - Newser
Real time breakdown of Immunovant Inc. stock performanceCPI Data & Fast Gaining Stock Strategy Reports - Newser
What indicators show strength in Immunovant Inc.Quarterly Earnings Report & Weekly Watchlist for Hot Stocks - Newser
Using economic indicators to assess Immunovant Inc. potentialMarket Risk Report & Low Risk High Win Rate Stock Picks - Newser
Immunovant Inc. stock outlook for YEARJuly 2025 Review & Fast Gaining Stock Reports - Newser
Is Immunovant Inc. stock poised for growthMarket Movement Recap & Free Weekly Watchlist of Top Performers - Newser
Can momentum traders help lift Immunovant Inc.Weekly Volume Report & Entry Point Confirmation Signals - Newser
Long term hold vs stop loss in Immunovant Inc.Layoff News & Expert Approved Momentum Trade Ideas - Newser
What’s next for Immunovant Inc. stockJuly 2025 Analyst Calls & Free High Return Stock Watch Alerts - khodrobank.com
Short interest data insights for Immunovant Inc.July 2025 Patterns & Fast Entry and Exit Trade Plans - Newser
Immunovant Inc. stock trend outlook and recovery pathPortfolio Value Summary & Low Volatility Stock Suggestions - Newser
Real time social sentiment graph for Immunovant Inc.July 2025 News Drivers & Proven Capital Preservation Tips - Newser
Should you avoid Immunovant Inc. stock right nowJuly 2025 Update & Advanced Swing Trade Entry Alerts - khodrobank.com
Regression analysis insights on Immunovant Inc. performanceQuarterly Profit Review & Expert Approved Momentum Ideas - Newser
Published on: 2025-09-01 10:52:28 - Newser
Is Immunovant Inc. a play on infrastructure spendingTrend Reversal & Safe Entry Zone Tips - khodrobank.com
Risk vs reward if holding onto Immunovant Inc.CEO Change & AI Forecasted Entry/Exit Points - Newser
Is a relief rally coming for Immunovant Inc. holders2025 Performance Recap & Real-Time Volume Analysis - Newser
Immunovant Inc. Inches Above Key Support — Safe to Hold2025 Pullback Review & Weekly Stock Breakout Alerts - beatles.ru
Technical Charts Suggest Momentum Shift in Immunovant Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
Published on: 2025-08-31 15:24:35 - Newser
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunovant Inc Azioni (IMVT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Geffner Michael | Chief Medical Officer |
Jul 23 '25 |
Sale |
18.15 |
2,385 |
43,288 |
221,825 |
| Geffner Michael | Chief Medical Officer |
Jul 09 '25 |
Sale |
17.24 |
1,160 |
19,998 |
224,210 |
| Stout Jay S | Chief Technology Officer |
Jul 09 '25 |
Sale |
17.24 |
1,519 |
26,188 |
207,724 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):